为了达到Nasdaq的上市要求, TransCode治疗法执行了33对33的逆向股票分割。 TransCode Therapeutics executes 1-for-33 reverse stock split to meet Nasdaq listing requirements.

RNA肿瘤公司TransCode治疗公司宣布从2024年12月4日起对33股进行逆向股票分割,以提振其股票价格并满足Nasdaq的上市要求。 TransCode Therapeutics, an RNA oncology company, has announced a 1-for-33 reverse stock split effective December 4, 2024, to boost its stock price and meet Nasdaq listing requirements. 分裂的目的是帮助该公司继续在Nasdaq资本市场上进行交易。 The split aims to help the company continue trading on the Nasdaq Capital Market. 随着TransCode利用其专利TTX纳米粒子平台开发更有效的癌症治疗方法, This move comes as TransCode works on developing more effective cancer treatments using its proprietary TTX nanoparticle platform.